%0 Journal Article
%A Farooq, Minaam
%A Scalia, Gianluca
%A Umana, Giuseppe E
%A Parekh, Urja
%A Naeem, Faiza
%A Abid, Sayeda Fatima
%A Khan, Muhammad Hammad
%A Zahra, Shah Gul
%A Sarkar, Hrishikesh P
%A Chaurasia, Bipin
%T A Systematic Review of Nanomedicine in Glioblastoma Treatment: Clinical Efficacy, Safety, and Future Directions.
%J Brain Sciences
%V 13
%N 12
%@ 2076-3425
%C Basel
%I MDPI AG
%M DKFZ-2023-02810
%P 1727
%D 2023
%X (1) Background: Glioblastoma (GBM) is categorized as a grade IV astrocytoma by the World Health Organization (WHO), representing the most aggressive and prevalent form of glioma. It presents a significant clinical challenge, with limited treatment options and poor prognosis. This systematic review evaluates the efficacy and safety of various nanotherapy approaches for GBM and explores future directions in tumor management. Nanomedicine, which involves nanoparticles in the 1-100 nm range, shows promise in improving drug delivery and targeting tumor cells. (2) Methods: Following PRISMA guidelines, a systematic search of databases including Google Scholar, NCBI PubMed, Cochrane Library, and ClinicalTrials.gov was conducted to identify clinical trials on GBM and nanomedicine. The primary outcome measures were median overall survival, progression-free survival, and quality of life assessed through Karnofsky performance scores. The safety profile was assessed by adverse events. (3) Results: The analysis included 225 GBM patients, divided into primary and recurrent sub-populations. Primary GBM patients had a median overall survival of 6.75 months, while recurrent GBM patients had a median overall survival of 9.7 months. The mean PFS period was 2.3 months and 3.92 months in primary GBM and recurrent GBM patients, respectively. Nanotherapy showed an improvement in quality of life, with KPS scores increasing after treatment in recurrent GBM patients. Adverse events were observed in 14.2
%K glioblastoma (Other)
%K molecular markers (Other)
%K nanomedicine (Other)
%K nanoparticles (Other)
%K quality of life (Other)
%K theranostics (Other)
%F PUB:(DE-HGF)16
%9 Journal Article
%$ pmid:38137175
%2 pmc:PMC10742051
%R 10.3390/brainsci13121727
%U https://inrepo02.dkfz.de/record/286593